KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBITDA Margin (2017 - 2026)

Aquestive Therapeutics has reported EBITDA Margin over the past 9 years, most recently at 244.79% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 10108.0% year-over-year to 244.79%; the TTM value through Dec 2025 reached 188.09%, down 11141.0%, while the annual FY2025 figure was 188.09%, 11141.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 244.79% at Aquestive Therapeutics, down from 120.61% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 72.46% in Q1 2023 and troughed at 618.35% in Q2 2021.
  • A 5-year average of 143.5% and a median of 112.59% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 41458bps in 2022 and later crashed -17889bps in 2024.
  • Year by year, EBITDA Margin stood at 261.28% in 2021, then soared by 56bps to 115.63% in 2022, then soared by 47bps to 61.42% in 2023, then crashed by -134bps to 143.72% in 2024, then plummeted by -70bps to 244.79% in 2025.
  • Business Quant data shows EBITDA Margin for AQST at 244.79% in Q4 2025, 120.61% in Q3 2025, and 135.44% in Q2 2025.